Thin endometrium-related infertility (deficiency of spleen and kidney Yang)
Conditions
Interventions
test team:Menstrual regulation and pregnancy promotion pill, oral, 5g (50 pills), twice a day. Take it for 20 consecutive days from the 5th day of the menstrual cycle for 3 consecutive menstrual cycle
control group:Estradiol valerate tablets: Patients with regular menstruation began to take estradiol valerate tablets on the 9th day of menstruation, 2mg/ day, and have been taking until 2 weeks after
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. According to the diagnosis of thin endometrium; 2. TCM syndrome differentiation of deficiency of spleen and kidney Yang; 3. There are currently pregnant with needs and planners; 4. 20-40 years old (inclusive); 5. Menstrual cycle of 21-35 days, 3 consecutive natural cycles of ovulation, and the sex hormone levels are normal; 6. At least one side of the fallopian tube patency; 7. The informed consent process is fully compliant.
Exclusion criteria
Exclusion criteria: 1. Patients with myometrial lesions (such as severe adenomyosis with uterine cavity deformation, etc.), endometrial tuberculosis, and uterine embolism; 2. Patients with severe intrauterine adhesion; 3. Infertility caused by bilateral fallopian tube obstruction, uterine fibroids, endometrial polyps, immune factors, endometriosis or congenital dysplasia and malformation of the reproductive system; 4. Patients with polycystic ovary syndrome, premature ovarian failure, hyperprolactinemia, hypothyroidism and other metabolic diseases or other abnormal endocrine function that affect ovulation function; 5. Patients with severe hyperplasia of breast nodules; 6. Infertility caused by the abnormal reproductive function of the man; 7. Contraindications to the use of estrogen therapy (such as patients with active venous or arterial thromboembolic disease, breast cancer, known or suspected estrogen-dependent tumors, severe liver and kidney dysfunction, blood porphyria, otosclerosis, systemic lupus erythematosus, etc.); 8. Contraindications to the use of progesterone therapy (such as liver and kidney insufficiency, cardiovascular disease, hypertension, diabetes, epilepsy, undiagnosed vaginal bleeding, patients with a history of thrombosis and gallbladder disease, etc.); 9. People with severe cardiovascular and cerebrovascular diseases, liver, kidney and other diseases, mental illness and severe neurosis; 10. Persons allergic to known ingredients in the trial drug; 11. The investigator does not consider it appropriate to attend the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial thickness on ovulation day of the 3rd menstrual cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endometrial thickness at different time points during the observation period;Cycle pregnancy rate;Endometrial blood flow index at different ovulation days during the observation period;Changes of endometrial morphology and composition in different ovulation days during the observation period;The change value and effective rate of TCM syndromes at different time points during the observation period;The disappearance rate of single symptom of TCM at different time points during the observation period; | — |
Countries
China
Contacts
Public ContactRong Ling
Peking University Third Hospital
Outcome results
None listed